Inovio Pharmaceuticals, Inc. (INO)
INO Stock Price Chart
Explore Inovio Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze INO price movements and trends.
INO Company Profile
Discover essential business fundamentals and corporate details for Inovio Pharmaceuticals, Inc. (INO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Dec 1998
Employees
134.00
Website
https://www.inovio.comCEO
Jacqueline E. Shea
Description
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
INO Financial Timeline
Browse a chronological timeline of Inovio Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Aug 2026
EPS estimate is -$0.28, while revenue estimate is $533.33k.
Earnings released on 13 May 2026
EPS came in at -$0.28 surpassing the estimated -$0.35 by +20.00%.
Earnings released on 12 Mar 2026
EPS came in at $0.31 surpassing the estimated -$0.37 by +183.78%.
Earnings released on 10 Nov 2025
EPS came in at -$0.44 surpassing the estimated -$0.51 by +13.73%.
Earnings released on 12 Aug 2025
EPS came in at -$0.61 surpassing the estimated -$0.63 by +3.17%.
Earnings released on 13 May 2025
EPS came in at -$0.51 surpassing the estimated -$0.74 by +31.08%, while revenue for the quarter reached $65.34k , beating expectations by +553.43%.
Earnings released on 18 Mar 2025
EPS came in at -$0.69 surpassing the estimated -$0.87 by +20.69%, while revenue for the quarter reached $116.99k , beating expectations by +133.99%.
Earnings released on 14 Nov 2024
EPS came in at -$0.89 surpassing the estimated -$1.20 by +25.83%.
Earnings released on 8 Aug 2024
EPS came in at -$1.19 falling short of the estimated -$1.15 by -3.48%, while revenue for the quarter reached $100.76k , missing expectations by -16.03%.
Earnings released on 13 May 2024
EPS came in at -$1.31 falling short of the estimated -$1.08 by -21.30%.
Earnings released on 6 Mar 2024
EPS came in at -$1.12 surpassing the estimated -$1.27 by +11.81%, while revenue for the quarter reached $102.65k , missing expectations by -69.81%.
Stock split effective on 25 Jan 2024
Shares were split 1 : 12 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 Nov 2023
EPS came in at -$1.08 surpassing the estimated -$1.56 by +30.77%, while revenue for the quarter reached $388.45k , beating expectations by +253.13%.
Earnings released on 9 Aug 2023
EPS came in at -$1.56 surpassing the estimated -$1.68 by +7.14%, while revenue for the quarter reached $225.97k , missing expectations by -13.09%.
Earnings released on 10 May 2023
EPS came in at -$1.92 falling short of the estimated -$1.68 by -14.29%, while revenue for the quarter reached $114.94k , missing expectations by -57.43%.
Earnings released on 1 Mar 2023
EPS came in at -$2.52 falling short of the estimated -$1.92 by -31.25%, while revenue for the quarter reached $124.67k , missing expectations by -63.26%.
Earnings released on 8 Nov 2022
EPS came in at -$1.80 surpassing the estimated -$3.48 by +48.28%, while revenue for the quarter reached $9.15m , beating expectations by +1.37k%.
Earnings released on 9 Aug 2022
EPS came in at -$5.52 falling short of the estimated -$3.60 by -53.33%, while revenue for the quarter reached $784.40k , beating expectations by +48.28%.
Earnings released on 10 May 2022
EPS came in at -$4.32 falling short of the estimated -$3.36 by -28.57%, while revenue for the quarter reached $199.07k , missing expectations by -74.25%.
Earnings released on 1 Mar 2022
EPS came in at -$6.00 falling short of the estimated -$3.96 by -51.52%, while revenue for the quarter reached $839.12k , missing expectations by -66.72%.
Earnings released on 9 Nov 2021
EPS came in at -$3.48 surpassing the estimated -$3.96 by +12.12%, while revenue for the quarter reached $291.70k , missing expectations by -69.93%.
Earnings released on 9 Aug 2021
EPS came in at -$4.68 falling short of the estimated -$3.00 by -56.00%, while revenue for the quarter reached $272.82k , missing expectations by -0.06%.
INO Stock Performance
Access detailed INO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
